DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award

Defense Health Agency Contracting Activity - DHACAAmount not specifiedDue Sep 30, 2026

Deadline: Sep 30, 2026
Posted: May 4, 2026
Award amount: Amount not specified
Focus areas: Science and Technology and other Research and Development

Who can apply

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

About this grant

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation. Distinctive Features: Potential impact and innovation are important features of the TIA. Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, the strength of the application should rely on the approach.

Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.